Kristin Wynholds - May 31, 2022 Form 4 Insider Report for Better Therapeutics, Inc. (BTTX)

Role
Chief Product Officer
Signature
/s/ Mark Heinen, Attorney-in-Fact
Stock symbol
BTTX
Transactions as of
May 31, 2022
Transactions value $
$12,420
Form type
4
Date filed
12/2/2022, 03:15 PM
Previous filing
Apr 4, 2022
Next filing
Apr 21, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BTTX Common Stock Award $7.73K +5.02K +5.58% $1.54 95K May 31, 2022 Direct F1
transaction BTTX Common Stock Award $4.69K +3.78K +3.98% $1.24 98.8K Nov 30, 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired under the Better Therapeutics, Inc. 2021 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).